16-2085280-C-G
Variant summary
Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PVS1PM2PP5_Moderate
The NM_000548.5(TSC2):c.4620C>G(p.Tyr1540*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Synonymous variant affecting the same amino acid position (i.e. Y1540Y) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000548.5 stop_gained
Scores
Clinical Significance
Conservation
Publications
- tuberous sclerosisInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- tuberous sclerosis 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), G2P, Genomics England PanelApp, Ambry Genetics
- lymphangioleiomyomatosisInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- tuberous sclerosis complexInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 12 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000548.5. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| TSC2 | NM_000548.5 | MANE Select | c.4620C>G | p.Tyr1540* | stop_gained | Exon 36 of 42 | NP_000539.2 | ||
| TSC2 | NM_001406663.1 | c.4617C>G | p.Tyr1539* | stop_gained | Exon 36 of 42 | NP_001393592.1 | |||
| TSC2 | NM_001114382.3 | c.4551C>G | p.Tyr1517* | stop_gained | Exon 35 of 41 | NP_001107854.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| TSC2 | ENST00000219476.9 | TSL:5 MANE Select | c.4620C>G | p.Tyr1540* | stop_gained | Exon 36 of 42 | ENSP00000219476.3 | ||
| TSC2 | ENST00000350773.9 | TSL:1 | c.4551C>G | p.Tyr1517* | stop_gained | Exon 35 of 41 | ENSP00000344383.4 | ||
| TSC2 | ENST00000401874.7 | TSL:1 | c.4419C>G | p.Tyr1473* | stop_gained | Exon 34 of 40 | ENSP00000384468.2 |
Frequencies
GnomAD3 genomes Cov.: 34
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 34
ClinVar
Submissions by phenotype
Tuberous sclerosis 2 Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. ClinVar contains an entry for this variant (Variation ID: 49849). This premature translational stop signal has been observed in individual(s) with tuberous sclerosis (PMID: 20633017, 24271014). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Tyr1540*) in the TSC2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TSC2 are known to be pathogenic (PMID: 10205261, 17304050).
TSC2-related disorder Pathogenic:1
The TSC2 c.4620C>G variant is predicted to result in premature protein termination (p.Tyr1540*). This variant was reported in patients with Tuberous sclerosis (Table 1 in Qin W et al 2010. PubMed ID: 20633017; Table 2 in Tyburczy ME et al 2013. PubMed ID: 24271014). Of note, another nonsense variant affecting the same amino acid (c.4620C>A, p.Tyr1540*) has also been reported to be pathogenic for Tuberous sclerosis (HGMD database, Reyna-Fabián. 2020. PubMed ID: 32313033). This variant has not been reported in a large population database, indicating this variant is rare. Nonsense variants in TSC2 are expected to be pathogenic. This variant is interpreted as pathogenic.
Tuberous sclerosis syndrome Other:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at